The GLP is committed to full transparency. Download and review our 2019 Annual Report

Gene therapy study produces promising results for hemophilia B patients

| September 30, 2013
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

A fraction of patients with a common form of the bleeding disorder hemophilia develop anallergic reaction to the blood-clotting treatment they need to keep them alive. But using gene therapy, University of Florida researchers were able to reverse this reaction and provide long-lasting treatment for the disease in an animal model, according to findings published today in the journal EMBO Molecular Medicine.

If successful in humans, gene therapy could not only provide much-needed therapy for patients with hemophilia B, but also spare them from costly and difficult treatment regimens, said Roland Herzog, Ph.D., a professor of pediatrics in the UF College of Medicine and a senior author on the paper.

Read the full, original story here: Gene therapy study produces promising results for hemophilia B patients

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend